Biblio
Export 796 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is P [Clear All Filters]
“Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice.”, Nat Med, vol. 20, no. 6, pp. 659-63, 2014.
, “Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice.”, Nat Med, vol. 20, no. 6, pp. 659-63, 2014.
, “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
,